DE69727398T2 - Zusammensetzungen und verfahren zur topischen anwendungen von wirkstoffen - Google Patents

Zusammensetzungen und verfahren zur topischen anwendungen von wirkstoffen Download PDF

Info

Publication number
DE69727398T2
DE69727398T2 DE69727398T DE69727398T DE69727398T2 DE 69727398 T2 DE69727398 T2 DE 69727398T2 DE 69727398 T DE69727398 T DE 69727398T DE 69727398 T DE69727398 T DE 69727398T DE 69727398 T2 DE69727398 T2 DE 69727398T2
Authority
DE
Germany
Prior art keywords
pharmaceutical
microparticulate
composition
dissolved
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69727398T
Other languages
German (de)
English (en)
Other versions
DE69727398D1 (de
Inventor
W. David OSBORNE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tolmar Therapeutics Inc
Original Assignee
ViroTex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViroTex Corp filed Critical ViroTex Corp
Application granted granted Critical
Publication of DE69727398D1 publication Critical patent/DE69727398D1/de
Publication of DE69727398T2 publication Critical patent/DE69727398T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DE69727398T 1996-09-11 1997-09-10 Zusammensetzungen und verfahren zur topischen anwendungen von wirkstoffen Expired - Lifetime DE69727398T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US712454 1996-09-11
US08/712,454 US5863560A (en) 1996-09-11 1996-09-11 Compositions and methods for topical application of therapeutic agents
PCT/US1997/015919 WO1998010746A1 (en) 1996-09-11 1997-09-10 Compositions and methods for topical application of therapeutic agents

Publications (2)

Publication Number Publication Date
DE69727398D1 DE69727398D1 (de) 2004-03-04
DE69727398T2 true DE69727398T2 (de) 2004-11-25

Family

ID=24862185

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69727398T Expired - Lifetime DE69727398T2 (de) 1996-09-11 1997-09-10 Zusammensetzungen und verfahren zur topischen anwendungen von wirkstoffen

Country Status (11)

Country Link
US (3) US5863560A (cg-RX-API-DMAC7.html)
EP (1) EP0957900B1 (cg-RX-API-DMAC7.html)
JP (2) JP4276298B2 (cg-RX-API-DMAC7.html)
AT (1) ATE258426T1 (cg-RX-API-DMAC7.html)
AU (1) AU737365B2 (cg-RX-API-DMAC7.html)
CA (1) CA2265461C (cg-RX-API-DMAC7.html)
DE (1) DE69727398T2 (cg-RX-API-DMAC7.html)
DK (1) DK0957900T3 (cg-RX-API-DMAC7.html)
ES (1) ES2212128T3 (cg-RX-API-DMAC7.html)
PT (1) PT957900E (cg-RX-API-DMAC7.html)
WO (1) WO1998010746A1 (cg-RX-API-DMAC7.html)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863560A (en) * 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US20030157036A1 (en) * 2002-02-20 2003-08-21 Osborne David W. Topical dapsone for the treatment of acne
US6787157B1 (en) * 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
RU2148396C1 (ru) * 1998-08-25 2000-05-10 Пермское научно-производственное объединение "Биомед" Способ определения активного вещества в дифильных мазевых основах
AU2001233174A1 (en) * 2000-01-31 2001-08-07 Engelhard Corporation Surfactant free topical compositions and method for rapid preparation thereof
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20020193321A1 (en) * 2000-12-12 2002-12-19 Mohan Vishnupad Dual dispenser for aesthitically acceptable delivery of anhydrous skin treatment compositions
US6495596B1 (en) 2001-03-23 2002-12-17 Biozibe Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
US6998421B2 (en) 2001-06-07 2006-02-14 Biozone Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase - 2
US6475526B1 (en) 2001-06-05 2002-11-05 Jeffrey B. Smith Zinc containing compositions for anti-viral use
US20040072810A1 (en) 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
US20030144362A1 (en) * 2002-01-28 2003-07-31 Utterberg David S. High viscosity antibacterials for cannulae
US20050042240A1 (en) * 2002-01-28 2005-02-24 Utterberg David S. High viscosity antibacterials
AU2003231571A1 (en) * 2002-04-30 2003-11-17 Mochida Pharmaceutical Co., Ltd. External preparation enhanced in systemic property of vidarabine
US20040086469A1 (en) * 2002-10-30 2004-05-06 Osborne David W. Protectant for UV-induced skin damage
US20080274209A1 (en) * 2002-11-04 2008-11-06 Integritas Pharma, Inc. Methods of treating inflammation
US6855341B2 (en) * 2002-11-04 2005-02-15 Jeffrey B. Smith Anti-viral compositions and methods of making and using the anti-viral compositions
JP4591746B2 (ja) * 2002-12-03 2010-12-01 大正製薬株式会社 難溶性抗ウイルス成分含有水溶性外用剤組成物
US20050037033A1 (en) * 2003-05-23 2005-02-17 Program For Appropriate Technology In Health Microbicidal compositions and methods and use
US7186416B2 (en) * 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
US20060229258A1 (en) * 2003-07-30 2006-10-12 Daniela Serikaku Steroidal compositions containing hydroxycarboxylic acids and methods of using the same
JP2007533606A (ja) * 2003-08-13 2007-11-22 キューエルティー・ユーエスエイ・インコーポレーテッド ダプソンを含む乳化組成物
US20060204526A1 (en) * 2003-08-13 2006-09-14 Lathrop Robert W Emulsive composition containing Dapsone
US20050191338A1 (en) * 2004-01-30 2005-09-01 Lifeng Kang Transdermal drug delivery composition comprising a small molecule gel and process for the preparation thereof
WO2006004759A2 (en) * 2004-06-29 2006-01-12 Mcclellan Stephanie N Topical compositions for anti-aging
US20060024372A1 (en) * 2004-07-29 2006-02-02 Utterberg David S High viscosity antibacterials
US7718674B2 (en) * 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
WO2006037047A2 (en) * 2004-09-27 2006-04-06 Bridge Pharma, Inc. The r-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
AU2005305157B2 (en) 2004-10-27 2011-09-01 Oklahoma Medical Research Foundation Adrenocorticotropic hormone analogs and related methods
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
WO2006113796A2 (en) * 2005-04-20 2006-10-26 Xylos Corporation Microbial cellulose materials for use in transdermal drug delivery system
US20060271262A1 (en) * 2005-05-24 2006-11-30 Mclain Harry P Iii Wireless agricultural network
WO2008018854A2 (en) * 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
US20100154146A1 (en) 2008-07-02 2010-06-24 S.C. Johnson & Son, Inc. Carpet decor and setting solution compositions
US8846154B2 (en) 2005-06-07 2014-09-30 S.C. Johnson & Son, Inc. Carpet décor and setting solution compositions
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
ITMI20051417A1 (it) * 2005-07-22 2007-01-23 Mipharm S P A Formulazione topica in forma di gel contenente come ingredienti attivi ciclovit e lidocaina
WO2007016450A2 (en) * 2005-07-29 2007-02-08 Beth Israel Deaconess Medical Center Methods for treating or preventing reactivation of a latent herpesvirus infection
CN101297034A (zh) 2005-08-24 2008-10-29 洛克菲勒大学 Ply-gbs突变溶素
US20070071705A1 (en) * 2005-09-29 2007-03-29 De Oliveira Monica A M Topical anti-microbial compositions
RS52671B (sr) 2005-10-12 2013-06-28 Unimed Pharmaceuticals Llc Poboljšani gel testosterona i postupak korišćenja
JP2007320886A (ja) * 2006-05-31 2007-12-13 Isp Japan Kk 含水ゲル状シート剤及びその製造方法
US7592458B2 (en) * 2006-07-21 2009-09-22 Wright George E Dermal anesthetic compounds and pharmaceutical compositions for inducing local anesthesia and mitigating neuropathic pain
WO2009108147A1 (en) 2008-02-27 2009-09-03 Qlt Usa, Inc. Dapsone to treat rosascea
US20100029781A1 (en) * 2008-06-04 2010-02-04 Morris Jerome A Methods for preparation of anti-acne formulation and compositions prepared thereby
JP5732397B2 (ja) 2008-10-10 2015-06-10 ルソメディカメンタ, エス.エー.Lusomedicamenta, S.A. 抗菌性ファージペプチド及びその使用法
ES2761835T3 (es) 2009-02-06 2020-05-21 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Fagos antibacterianos, péptidos de fagos y métodos de uso de los mismos
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
US8999302B1 (en) 2009-10-22 2015-04-07 Aplicare, Inc. Skin dye protectant formulations
PT104837A (pt) 2009-11-24 2011-05-24 Technophage Investiga O E Desenvolvimento Em Biotecnologia S A P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
RU2614114C2 (ru) 2010-09-17 2017-03-22 Текнифар-Индустриа Текника Фармасьютика, С.А Бактериофаги, фаговые пептиды и способы их применения
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
ES2498217T5 (es) 2010-10-21 2018-03-19 Galderma S.A. Composición en forma de gel basada en brimonidina
MX383544B (es) 2011-04-21 2025-03-14 Univ Rockefeller Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas
JP6039145B2 (ja) * 2011-05-25 2016-12-07 ノバリック ゲーエムベーハー 半フッ化アルカンを基礎にした局所薬学的組成物
CA2840733A1 (en) * 2011-06-30 2013-01-03 Allergan, Inc. Retinoid topical compositions and methods for treating skin conditions
US9962419B2 (en) 2012-03-19 2018-05-08 Tecnifar—Industria Tecnica Farmaceutica, S.A. Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
EP2895144B1 (en) 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
MX363182B (es) 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
DK2922528T3 (en) * 2012-11-20 2017-09-18 Allergan Inc TOPICAL DAPSON AND DAPSON / ADAPALEN COMPOSITIONS AND PROCEDURES FOR USE THEREOF
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US20160051499A1 (en) 2014-07-31 2016-02-25 Allergan, Inc. Comparative efficacy and tolerability of dapsone 5% in adult versus adolescent females with acne vulgaris
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
EP3722274B1 (en) 2015-09-30 2023-06-07 Novaliq GmbH 2-perfluorobutyl pentane for ophthalmic administration
AU2016348527A1 (en) * 2015-11-04 2018-05-24 Allergan, Inc. Methods of treatment of acne vulgaris using topical dapsone compositions
DK3442480T3 (da) 2016-06-23 2020-01-13 Novaliq Gmbh Fremgangsmåde til topisk indgivelse
KR102614858B1 (ko) 2016-09-22 2023-12-18 노바리크 게엠베하 안검염 치료에 사용되는 약제학적 조성물
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
MX381639B (es) 2016-12-23 2025-03-13 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
PL3612228T3 (pl) 2017-04-21 2024-04-08 Dermaliq Therapeutics, Inc. Kompozycje jodu
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
JP7814839B2 (ja) 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
US20210062137A1 (en) 2017-12-22 2021-03-04 The Rockefeller University Recombinant pseudomonas aeruginosa lysins
US11576893B2 (en) 2018-03-02 2023-02-14 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
AU2019246035B2 (en) 2018-03-28 2024-07-18 Novaliq Gmbh Pharmaceutical composition comprising timolol
JP7855312B2 (ja) 2018-04-27 2026-05-08 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
CA3102689C (en) 2018-06-04 2023-08-29 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
US11510855B2 (en) 2018-09-27 2022-11-29 Dermaliq Therapeutics, Inc. Topical sunscreen formulation
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
WO2020181395A1 (en) 2019-03-14 2020-09-17 Crescita Therapeutics Inc. Rinse-off compositions and uses thereof for delivery of active agents
US12098372B2 (en) 2019-12-30 2024-09-24 Eligo Bioscience Microbiome modulation of a host by delivery of DNA payloads with minimized spread
US11746352B2 (en) 2019-12-30 2023-09-05 Eligo Bioscience Microbiome modulation of a host by delivery of DNA payloads with minimized spread
BR112022015104A2 (pt) 2020-01-31 2022-09-27 Arcutis Biotherapeutics Inc Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição
US11617773B2 (en) 2020-04-08 2023-04-04 Eligo Bioscience Elimination of colonic bacterial driving lethal inflammatory cardiomyopathy
KR20220164757A (ko) 2020-04-08 2022-12-13 엘리고 바이오사이언스 마이크로바이옴-연관 질환 또는 장애의 예방, 치료 또는 치유를 위한 마이크로바이옴의 유전자 요법에 의한 미생물총 기능의 조절
DE21179356T1 (de) 2020-06-12 2022-02-17 Eligo Bioscience Spezifische entkolonisierung von antibiotikaresistenten bakterien für prophylaktische zwecke
WO2022003209A1 (en) 2020-07-03 2022-01-06 Eligo Bioscience Method of containment of nucleic acid vectors introduced in a microbiome population
EP4210756A4 (en) 2020-09-11 2025-12-31 Pinnacle Biologics Inc PHOTODYNAMIC THERAPY COMPOSITIONS AND THEIR METHODS OF USE
CN116963717A (zh) 2020-12-04 2023-10-27 阿尔库缇斯生物疗法股份有限公司 具有抗真菌性能的局部用罗氟司特制剂
WO2022144382A1 (en) 2020-12-30 2022-07-07 Eligo Bioscience Chimeric receptor binding proteins resistant to proteolytic degradation
WO2022169615A1 (en) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
WO2023057599A1 (en) 2021-10-07 2023-04-13 Eligo Bioscience Methods involving bacteroides strain replacement
WO2023057598A1 (en) 2021-10-07 2023-04-13 Eligo Bioscience Methods involving bacterial strain replacement
IL313866A (en) 2021-12-28 2024-08-01 Arcutis Biotherapeutics Inc Topical roflomilest spray foams
IL319352A (en) 2022-09-15 2025-05-01 Arcutis Biotherapeutics Inc Pharmaceutical preparations of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867533A (en) * 1968-12-20 1975-02-18 Basf Wyandotte Corp Preparation of aqueous gel compositions containing a water-insoluble organic ingredient
US4731359A (en) * 1980-04-21 1988-03-15 University Of Southern California Prolonged action drug formulation
US4507287A (en) * 1983-06-20 1985-03-26 Dixon Glen J Preparation and method for the treatment of acne
US4853439A (en) * 1987-10-09 1989-08-01 Gaf Corporation Water-soluble complexes of water-insoluble organic compounds
US5180576A (en) * 1991-08-30 1993-01-19 Church & Dwight Co., Inc. Anticalculus dentifrices
GB2260080A (en) * 1991-10-04 1993-04-07 Rhone Poulenc Rorer Ltd Gelled alginate compositions
AU670777B2 (en) * 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
IL104283A (en) * 1992-12-30 1996-12-05 Agis Ind 1983 Ltd Non-emulsion antiviral topical pharmaceutical composition comprising acyclovir an aqueous gel agent and an alkali oleate
GB9408545D0 (en) * 1994-04-29 1994-06-22 Zyma Sa Compositions
EP0780126A1 (en) * 1994-09-06 1997-06-25 Nippon Kayaku Kabushiki Kaisha Ointment
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5863560A (en) * 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents

Also Published As

Publication number Publication date
CA2265461C (en) 2004-11-30
US6060085A (en) 2000-05-09
PT957900E (pt) 2004-06-30
AU4261097A (en) 1998-04-02
JP2006096774A (ja) 2006-04-13
WO1998010746A1 (en) 1998-03-19
JP4276298B2 (ja) 2009-06-10
EP0957900A1 (en) 1999-11-24
DE69727398D1 (de) 2004-03-04
AU737365B2 (en) 2001-08-16
US6620435B1 (en) 2003-09-16
CA2265461A1 (en) 1998-03-19
EP0957900B1 (en) 2004-01-28
DK0957900T3 (da) 2004-06-01
ATE258426T1 (de) 2004-02-15
US5863560A (en) 1999-01-26
JP2001500863A (ja) 2001-01-23
ES2212128T3 (es) 2004-07-16

Similar Documents

Publication Publication Date Title
JP4276298B2 (ja) 治療薬の局所適用のための組成物および方法
DE69029804T2 (de) VEHIKEL MIT LANGSAMER FREISETZUNG ZUR VERMINDERUNG DER HAUTREIZUNG TOPISCHER retinoidhaltiger MITTEL
EP0814776B1 (de) Topisch applizierbare pharmazeutische zusammensetzung, verfahren zu ihrer herstellung und verwendung der zusammensetzung
DE69935135T2 (de) Topische hormonhaltige zusammensetzung mit systemischer wirkung
DE69919594T2 (de) Topische zusammensetzungen zur prostaglandin e1 abgabe
DE3650734T2 (de) Pharmazeutische Träger zum Reduzieren des transdermalen Flusses
DE69715049T2 (de) Tranilast enthaltendes externum und verfahren zu dessen herstellung
JP2001500863A5 (cg-RX-API-DMAC7.html)
DE2605242A1 (de) Entzuendungshemmendes arzneimittel zur oertlichen verwendung
DE60315939T2 (de) Pharmazeutische zusammensetzung enthaltend ein androgen
DE2721831A1 (de) Entzuendungshemmende, topisch anzuwendende arzneipraeparate
DE69829510T2 (de) Stabile Zubereitung enthaltend Acetylsalicylsäure und Siliconöl zur äusseren Anwendung
DE4111982C2 (de) Stabile kleinpartikuläre Liposomenzubereitungen, deren Herstellung und Verwendung
DD298352A5 (de) Tretinoin enthaltende zubereitung und verfahren zu ihrer herstellung
WO1994003156A1 (de) Pharmazeutische und/oder kosmetische zubereitung sowie die verwendung einer derartigen zubereitung
DE3411225C2 (cg-RX-API-DMAC7.html)
DE69019151T2 (de) Salbe enthaltend Deprodone proprionate.
DE2601489A1 (de) Tretinoin enthaltende gelpraeparate
EP2056781B1 (de) Wasserfreie, harnstoffhaltige, dermatologische oder kosmetische zubereitung
DE2316597A1 (de) Dermatologische zubereitung
DE69402259T2 (de) Zusammensetzungen enthaltend 8-Hydroxychinolin zur Behandlung hyperproliferativer Hautkrankheiten
DE69008117T2 (de) Endermaler Arzneistoff in einer Gelbasis.
DE3020616C2 (cg-RX-API-DMAC7.html)
DE10015463B4 (de) Creme in Form einer überwässerten Wasser-in-Öl-Emulsion
DE69735091T2 (de) Synergistische Gold enthaltende Zusammensetzungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: QLT USA, INC. (N.D.GES.D. STAATES DELAWARE), , US

8328 Change in the person/name/address of the agent

Representative=s name: PATENTANWAELTE LEIFERT & STEFFAN, 40213 DUESSELDOR